{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T08:32:40Z","timestamp":1774600360531,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,27]],"date-time":"2014-08-27T00:00:00Z","timestamp":1409097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.antiviral.2014.07.014","type":"journal-article","created":{"date-parts":[[2014,8,6]],"date-time":"2014-08-06T22:15:35Z","timestamp":1407363335000},"page":"94-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":469,"special_numbering":"C","title":["Nitazoxanide: A first-in-class broad-spectrum antiviral agent"],"prefix":"10.1016","volume":"110","author":[{"given":"Jean-Fran\u00e7ois","family":"Rossignol","sequence":"first","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2014.07.014_b0005","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(02)11401-2","article-title":"Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomized controlled trial","volume":"360","author":"Amadi","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2014.07.014_b0010","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.virol.2014.05.015","article-title":"Nitazoxanide, an antiviral thiazolide, depletes ATP-sensitive intracellular Ca2+ stores","volume":"462\u2013463","author":"Ashiru","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2014.07.014_b0015","doi-asserted-by":"crossref","DOI":"10.4061\/2010\/891010","article-title":"In vitro susceptibility of canine influenza A (H3N8) virus to nitazoxanide and tizoxanide","volume":"2010","author":"Ashton","year":"2010","journal-title":"Vet. Med. Int."},{"key":"10.1016\/j.antiviral.2014.07.014_b0020","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/jac\/dki456","article-title":"Efficacy of nitazoxanide and paromomycin on biliary tract cryptosporidiosis in an immunosuppressed gerbil model","volume":"57","author":"Baishanbo","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2014.07.014_b0025","unstructured":"Belardo, G., La Frazia, S., Cenciarelli, O., Carta, S., Rossignol, J.F., Santoro, M.G., 2011. Nitazoxanide, a novel potential anti-influenza drug, acting in synergism with neuraminidase inhibitors. Poster presented at: 49th Infectious Disease Society of America Annual Meeting, Oct 20\u201323, 2011, Boston, Massachusetts. https:\/\/idsa.confex.com\/idsa\/2011\/webprogram\/Paper31075.html."},{"key":"10.1016\/j.antiviral.2014.07.014_b0035","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1128\/AAC.42.11.2877","article-title":"Comparative efficacy evaluation of dicationic carbazole compounds, nitazoxanide and paromomycin against Cryptosporidium parvum infections in a neonatal mouse model","volume":"42","author":"Blagburn","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.07.014_b0040","doi-asserted-by":"crossref","first-page":"387","DOI":"10.5414\/CPP38387","article-title":"Nitazoxanide: pharmacokinetics and metabolism in man","volume":"38","author":"Broekhuysen","year":"2000","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2014.07.014_b0045","first-page":"779","article-title":"Etude de diverses associations d\u2019anthelminthiques chez la souris","volume":"133","author":"Cavier","year":"1982","journal-title":"Rev. M\u00e9d. V\u00e9t."},{"issue":"155","key":"10.1016\/j.antiviral.2014.07.014_b0050","first-page":"21","article-title":"The anti-infective nitazoxanide shows strong immuno-modulating effects [abstract]","volume":"186","author":"Clerici","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2014.07.014_b0055","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.1021\/jm9010719","article-title":"Nitazoxanide kills replicating and non-replicating Mycobacterium tuberculosis and evades resistance","volume":"52","author":"De Carvalho","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2014.07.014_b0060","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1021\/ml200157f","article-title":"Nitazoxanide disrupts membrane potential and intra-bacterial pH homeostasis of Mycobacterium tuberculosis","volume":"2","author":"De Carvalho","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2014.07.014_b0065","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.coviro.2013.03.001","article-title":"Intervention strategies for emerging viruses: use of antivirals","volume":"3","author":"Debing","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2014.07.014_b0070","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nri3344","article-title":"The broad-spectrum antiviral functions of IFIT and IFITM proteins","volume":"13","author":"Diarmond","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.antiviral.2014.07.014_b0075","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1128\/AAC.40.10.2266","article-title":"In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms","volume":"40","author":"Dubreuil","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.07.014_b0080","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1053\/j.gastro.2009.07.056","article-title":"The anti-hepatic C agent nitazoxanide induces phosphorylation of eIF2-alpha via PKR activation","volume":"137","author":"Elazar","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2014.07.014_b0085","first-page":"687","article-title":"Experimentation des propri\u00e9t\u00e9s anthelminthiques de la nitazoxanide chez le chien, le chat et les ovins","volume":"131","author":"Euzeby","year":"1980","journal-title":"Rev. M\u00e9d. V\u00e9t."},{"key":"10.1016\/j.antiviral.2014.07.014_b0090","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1128\/AAC.00441-08","article-title":"Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora","volume":"53","author":"Finegold","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.07.014_b0095","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/jac\/dkr077","article-title":"Nitazoxanide is active against Clostridium difficile strains with reduced susceptibility to metronidazole","volume":"66","author":"Freeman","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2014.07.014_b0100","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1128\/AAC.00614-09","article-title":"Evaluation of new thiazolide\/thiadiazolide derivatives reveals nitro-group-independent efficacy against Cryptosporidium parvum","volume":"54","author":"Gargala","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.07.014_b0105","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1128\/AAC.01538-12","article-title":"Activity of halogeno-thiazolides against Cryptosporidium parvum in experimentally infected immunosuppressed gerbils (Meriones unguiculatus)","volume":"57","author":"Gargala","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.07.014_b0110","unstructured":"Gubareva, L.V., Marjuki, H., Mishin, V.P., Sleeman, K., Tamura, D., Chesnokov, A., De La Cruz, J., Villaneuva, J., Davis, T., 2014. Susceptibility of avian influenza A(H7N9) viruses to FDA approved and investigational antiviral drugs. Programme & Abstract Book, Influenza and Other Respiratory Virus Infections: Advances in Clinical Management. Third ISIRV-Antiviral Group Conference. Abstract P57, 83."},{"key":"10.1016\/j.antiviral.2014.07.014_b0115","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1473-3099(14)70717-0","article-title":"A randomized, double-blind, placebo controlled clinical trial of nitazoxanide in adults and adolescents with acute uncomplicated influenza","volume":"14","author":"Haffizulla","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.07.014_b0120","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1128\/AAC.01623-06","article-title":"In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004","volume":"51","author":"Hecht","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.07.014_b0125","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1128\/AAC.01159-06","article-title":"Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni","volume":"51","author":"Hoffman","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.07.014_b0130","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.antiviral.2014.02.012","article-title":"Treatment of norovirus infections: moving antivirals from the bench to the bedside","volume":"105","author":"Kaufman","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.07.014_b0135","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.antiviral.2007.08.005","article-title":"Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication","volume":"77","author":"Korba","year":"2008","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.07.014_b0140","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1128\/AAC.00078-08","article-title":"Studies of the potential for nitazoxanide or tizoxanide resistance in hepatitis C virus replicon-containing cell lines","volume":"52","author":"Korba","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.07.014_b0145","doi-asserted-by":"crossref","first-page":"11096","DOI":"10.1128\/JVI.01213-13","article-title":"Thiazolides, a new class of antiviral agents effective against rotavirus infection, target viral morphogenesis inhibiting viroplasm formation","volume":"83","author":"La Frazia","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.07.014_b0150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.14411\/fp.2003.003","article-title":"Long-lasting anticryptosporidial activity of nitazoxanide in an immunosuppressed rat model","volume":"50","author":"Li","year":"2003","journal-title":"Folia Parasitol. (Praha)"},{"key":"10.1016\/j.antiviral.2014.07.014_b0155","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1128\/AAC.44.9.2254-2258.2000","article-title":"In vitro and in vivo activities of nitazoxanide against Clostridium difficile","volume":"44","author":"McVay","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.07.014_b0160","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1128\/AAC.42.11.2836","article-title":"Nitazoxanide, a potential drug to eradicate Helicobacter pylori with no cross-resistance to metronidazole","volume":"42","author":"M\u00e9graud","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.07.014_b0165","unstructured":"Meneses, M.D.S., Duarte, R.S., Migowski, E.R., Ferreira, D.F., 2013. In vitro study on the effects of nitazoxanide on the replication of dengue virus and yellow fever virus. Poster Presented at the 28th International Conference on Antiviral Research (ICAR). Abstract #157, 101."},{"key":"10.1016\/j.antiviral.2014.07.014_b0170","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1086\/506351","article-title":"Nitazoxanide in the treatment of Clostridium difficile colitis","volume":"43","author":"Musher","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.07.014_b0175","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1086\/596552","article-title":"Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study","volume":"48","author":"Musher","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.07.014_b0180","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1046\/j.1365-2036.2001.01066.x","article-title":"Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from northern Peru","volume":"15","author":"Ortiz","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2014.07.014_b0185","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1128\/AAC.50.3.1112-1117.2006","article-title":"Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic species","volume":"50","author":"Pankuch","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.07.014_b0190","unstructured":"Romark Laboratories, L.C. Alinia\u00ae (nitazoxanide) prescribing information. 2007."},{"key":"10.1016\/j.antiviral.2014.07.014_b0195","first-page":"28216n","article-title":"Synthesis and antiparasitic activity of 2-benzamido nitrothiazoles","volume":"83","author":"Rossignol","year":"1975","journal-title":"Chem. Abstr."},{"key":"10.1016\/j.antiviral.2014.07.014_b0200","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/j.1365-2036.2006.03128.x","article-title":"Nitazoxanide in treatment of viral gastroenteritis: a randomized, double-blind, placebo-controlled clinical trial","volume":"24","author":"Rossignol","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2014.07.014_b0205","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2217\/17460913.3.5.539","article-title":"Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C","volume":"3","author":"Rossignol","year":"2008","journal-title":"Future Microbiol."},{"key":"10.1016\/j.antiviral.2014.07.014_b0210","doi-asserted-by":"crossref","first-page":"511","DOI":"10.4269\/ajtmh.1984.33.511","article-title":"Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana","volume":"33","author":"Rossignol","year":"1984","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.antiviral.2014.07.014_b0215","unstructured":"Rossignol, J.F., Santoro M.G., 2014. Activity of thiazolides against other respiratory viruses than influenza. Programme & Abstract Book, Influenza and Other Respiratory Virus Infections: Advances in Clinical Management. Third ISIRV-Antiviral Group Conference. Abstract P54, 81."},{"key":"10.1016\/j.antiviral.2014.07.014_b0220","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1039\/a806676k","article-title":"Synthesis and antibacterial activities of tizoxanide and its o-aryl glucuronide","author":"Rossignol","year":"1999","journal-title":"J. Chem. Res."},{"key":"10.1016\/j.antiviral.2014.07.014_b0230","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1086\/321008","article-title":"Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized double-blind placebo-controlled study of nitazoxanide","volume":"184","author":"Rossignol","year":"2001","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.07.014_b0235","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0140-6736(06)68852-1","article-title":"Effect of nitazoxanide in treating severe rotavirus diarrhea: a randomized, double-blind, placebo-controlled trial","volume":"368","author":"Rossignol","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2014.07.014_b0240","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1365-2036.2008.03781.x","article-title":"Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype-4","volume":"28","author":"Rossignol","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2014.07.014_b0245","doi-asserted-by":"crossref","first-page":"29798","DOI":"10.1074\/jbc.M109.029470","article-title":"Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at post-translational level","volume":"284","author":"Rossignol","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2014.07.014_b0250","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1053\/j.gastro.2008.11.037","article-title":"Improved virologic response in chronic hepatitis C genotype-4. Patients given nitazoxanide, peginterferon, and ribavirin","volume":"136","author":"Rossignol","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2014.07.014_b0255","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/MCG.0b013e3181bf9b15","article-title":"Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide","volume":"44","author":"Rossignol","year":"2010","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.antiviral.2014.07.014_b0260","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.trstmh.2011.11.007","article-title":"Nitazoxanide for the empiric treatment of pediatric infectious diarrhea","volume":"106","author":"Rossignol","year":"2012","journal-title":"Trans. R. Trop. Med. Hyg."},{"key":"10.1016\/j.antiviral.2014.07.014_b0265","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/rmv.703","article-title":"The host interactome of influenza virus presents new potential targets for antiviral drugs","volume":"21","author":"Shaw","year":"2011","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2014.07.014_b0270","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1743-422X-11-10","article-title":"Nitazoxanide inhibits the replication of Japanese encephalitis virus in cultured cells and in a mouse model","volume":"11","author":"Shi","year":"2014","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2014.07.014_b0275","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jinf.2011.08.002","article-title":"Norovirus gastroenteritis successfully treated with nitazoxanide","volume":"63","author":"Siddiq","year":"2011","journal-title":"J. Infect."},{"key":"10.1016\/j.antiviral.2014.07.014_b0280","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1128\/AAC.02556-13","article-title":"Antiviral susceptibility of variant influenza A (H3N2)v viruses isolated in the United States during 2011\u20132013","volume":"58","author":"Sleeman","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.07.014_b0285","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1021\/jm200153p","article-title":"Thiazolides as novel antiviral agents: I. Inhibition of hepatitis B virus","volume":"54","author":"Stachulski","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2014.07.014_b0290","doi-asserted-by":"crossref","first-page":"8670","DOI":"10.1021\/jm201264t","article-title":"Thiazolides as novel antiviral agents: II. Inhibition of the hepatitis C virus","volume":"54","author":"Stachulski","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2014.07.014_b0295","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/nbt.2391","article-title":"Systematic identification of synergistic drug pairs targeting HIV","volume":"30","author":"Tan","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2014.07.014_b0300","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.300","article-title":"Analyzing the relationship of QT interval and exposure to nitazoxanide, a prospective candidate for influenza antiviral therapy-A formal TQT study","author":"Taubel","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.antiviral.2014.07.014_b0305","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ijid.2008.09.014","article-title":"Nitazoxanide vs. probiotics for the treatment of acute rotavirus diarrhea in children: a randomized, single-blind controlled trial in Bolivian children","volume":"13","author":"Teran","year":"2009","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.07.014_b0310","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1128\/AAC.42.8.1959","article-title":"Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models","volume":"42","author":"Theodos","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.07.014_b0315","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.antiviral.2011.05.017","article-title":"Mutations in HCV non-structural genes do not contribute to resistance to nitazoxanide in replicon-containing cells","volume":"91","author":"Yon","year":"2011","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.07.014_b0320","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1586\/eri.12.104","article-title":"Development of novel entry inhibitors targeting emerging viruses","volume":"10","author":"Zhou","year":"2012","journal-title":"Expert Rev. Anti. Infect. Ther."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214002137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214002137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T17:10:18Z","timestamp":1649869818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354214002137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":62,"alternative-id":["S0166354214002137"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.07.014","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nitazoxanide: A first-in-class broad-spectrum antiviral agent","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Author. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}